GLP-1药物可能在PET扫描中错误地模仿癌症,造成误诊断,研究人员警告说。 GLP-1 drugs may falsely mimic cancer on PET scans, causing misdiagnosis, researchers warn.

根据2025年欧洲核医学协会会议所作的研究,用于2型糖尿病和体重减退的GLP-1受体激动剂可能导致FDG PET-CT扫描中异常的葡萄糖痕量器吸收、模仿癌症或炎症。 GLP-1 receptor agonists, used for type 2 diabetes and weight loss, may cause abnormal glucose tracer uptake on FDG PET-CT scans, mimicking cancer or inflammation, according to research presented at the 2025 European Association of Nuclear Medicine conference. 这些药物会改变葡萄糖新陈代谢和组织活动,导致肌肉、心脏和棕色脂肪品种中的痕量摄入增加,可能导致误诊、不必要的检测或延迟治疗。 These drugs alter glucose metabolism and tissue activity, leading to increased tracer uptake in muscles, heart, and brown fat—patterns that can result in misdiagnosis, unnecessary tests, or delayed treatment. 一项以联合王国为基础的审查发现,这些成像变化越来越普遍,但联合王国或美国没有国家准则处理这一问题。 A UK-based review found these imaging changes are increasingly common, yet no national guidelines in the UK or US address the issue. 研究人员敦促记录药物使用以避免错误,建议不要在扫描前停止药物,并根据澳大利亚的指导,建议禁食、晨成像和稳定的葡萄糖控制。 Researchers urge documenting medication use to avoid errors, advise against stopping the drugs before scans, and recommend fasting, morning imaging, and stable glucose control based on Australian guidance. 它们计划扩大数据收集,以便为今后的标准化议定书提供信息。 They plan to expand data collection to inform future standardized protocols.